Back to search

France· FR:60033389

BLEOMYCINE ACCORD 15000 UI, poudre pour solution injectable / pour perfusion

A bleomycin product containing sulfate de bléomycine, registered in France by ACCORD HEALTHCARE FRANCE. The same ATC class is registered in 15 of our 19 countries.

ATC L01DC01

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedBLEOMYCINE ACCORD 15000 UI, poudre po…ATCL01DC01REGISTER NO.FR:60033389PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Bleomycin is registered in 15 of 19 countries.

Countries holding a registration under ATC L01DC01 (bleomycin), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Bleomycin · ATC L01DC01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
SULFATE DE BLÉOMYCINE
Manufacturer
ACCORD HEALTHCARE FRANCE
Country
France (FR)
ATC code
L01DC01
ATC class
Bleomycin
Defined daily dose
3 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930116579
    1 flacon(s) en verre de 6 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

212 interactions on record for bleomycin.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Bleomycin · interactions on record

212 records

  • 33 severe
  • 105 moderate
  • 15 minor
  • 59 info

Most severe, free to view

  • CladribineL01BB04severe
  • Brentuximab vedotinL01FX05severe
  • Brentuximab vedotinL01XC12severe
  • Talimogene laherparepvecL01XL02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bleomycin in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bleomycin products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Bleomycin Accord, Bleomycin Baxter
  • Belgium · Bleomycine Accord
  • Czechia · Bleomycin Accord
  • Germany · Bleo-Cell, Bleomycin Accord
  • Denmark · Bleomycin Accord, Bleomycin Baxter
  • Spain · Bleomicina Accord, Bleomicina Viatris
  • Finland · Bleomycin Accord
  • United Kingdom (Northern Ireland) · Bleomycin, Bleomycin Accord Healthcare
  • Iceland · Bleomycin Baxter
  • Netherlands · Bleomycine Accord
  • Norway · Bleomycin Accord, Bleomycin Baxter
  • Poland · Bleomedac, Bleomycyna
  • Portugal · Bleomicina Accord
  • Romania · Bleomicină Accord
  • Sweden · Bleomycin Accord, Bleomycin Baxter

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8d4cd333-2358-4589-91d1-34e7185275ec
GET /v1/drugs/8d4cd333-2358-4589-91d1-34e7185275ec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60033389",
  "date_amm": "2017-12-07",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "SULFATE DE BLÉOMYCINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre pour solution injectable ou pour perfusion",
  "voies_administration": "intraartérielle;intramusculaire;intrapleurale;intratumorale;intraveineuse;sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about bleomycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.